Error loading player: No playable sources found
3500
Therapeutic Choice and the Pipeline for MASLD and MASH
Date
May 19, 2024
This product is not available for individual purchase, but it is available as part of the following products:
Full DDW 2024 On Demand Program available now!
SOCIETY: AASLD
Moderators
University of Alabama at Birmingham School of Medicine
Thomas Jefferson University
Tracks
Related Products
AASLD Presidential Plenary
ASSOCIATION OF GLUCAGON-LIKE PEPTIDE-1 AGONISTS WITH CIRRHOSIS AND HEPATOCELLULAR CANCER IN METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Human and Experimental Cholestasis
METABOLIC OUTCOMES AND KEY EFFICACY DATA FROM A PHASE 2 TRIAL EVALUATING COMBINATION OBETICHOLIC ACID AND BEZAFIBRATE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS
It's Not Over: Viral Hepatitis in the Modern Era
SOCIETY: AASLD
